Bayer considers expanding use of Nubeqa on new data from prostate cancer trial
Bayer said its drug Nubeqa was shown to slow the progression of a certain type of prostate cancer in a late-stage trial, bolstering growth prospects for one of the German drugmaker’s key pharmaceuticals. The drug is already approved in other prostate cancer treatments.
POPULAR POSTS
Portugal declares risk as wildfires hit the north of the country
September 17, 2024
UK to appoint nature envoy
September 17, 2024
Death tolls rises as Central Europe floods
September 17, 2024
LIVE STREAM